Galena Biopharma, Inc. (NASDAQ:GALE)

CAPS Rating: 1 out of 5

Results 1 - 4 of 4

Recs

0
Member Avatar DougD720 (< 20) Submitted: 7/17/2014 11:05:35 AM : Outperform Start Price: $2.65 GALE Score: +11.93

Neuvax, highly undervalued due to scandal, still solid company with an excellent pipeline.

Recs

0
Member Avatar herbertslojewski (73.80) Submitted: 7/7/2014 3:56:58 PM : Outperform Start Price: $2.94 GALE Score: +0.55

Great new anti-cancer developments.

Recs

0
Member Avatar manirg (59.84) Submitted: 3/11/2014 9:48:12 AM : Outperform Start Price: $3.37 GALE Score: -17.07

highly undervalued, huge potential, has 2 drugs approved

Recs

0
Member Avatar jgvega (< 20) Submitted: 2/23/2014 3:58:40 PM : Outperform Start Price: $3.92 GALE Score: -31.38

Great chances of being revenue positive towards the end of the year thanks to drug Abstral. Huge market potential for breast cancer drug NueVax (if passed by FDA. it has great chances). Positive ratings from many analysts. Oh, and it’s undervalued due to recently ended bear raid. All and all, great stock and price with multi bagger potential for 2014. check it out.

Results 1 - 4 of 4

Featured Broker Partners


Advertisement